PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders Post published:July 13, 2022 Post category:Press Release
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch Post published:July 5, 2022 Post category:Press Release
PharmaTher Announces Positive Results from Study of KETABET™ for Depression Post published:June 7, 2022 Post category:Press Release
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs Post published:April 12, 2022 Post category:Press Release
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation Post published:February 16, 2022 Post category:Press Release
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus Post published:February 1, 2022 Post category:Press Release
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS Post published:January 12, 2022 Post category:Press Release
PharmaTher Announces Publication of Research Data for KETABET™ Post published:January 4, 2022 Post category:Press Release
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Post published:December 21, 2021 Post category:Press Release
PharmaTher Announces Positive Research Results for LSD Microneedle Patch Post published:December 14, 2021 Post category:Press Release